FWM
SAGE

FSA Wealth Management’s Sage Therapeutics SAGE Stock Holding History

FSA Wealth Management’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-35
Closed -$319 – 586
2025
Q2 		$319 Hold
35
– – ﹤0.01% 535
2025
Q1 		$278 Hold
35
– – ﹤0.01% 497
2024
Q4 		$190 Hold
35
– – ﹤0.01% 554
2024
Q3 		$253 Buy
+35
New +$320 ﹤0.01% 549
2024
Q1 		$656 Hold
35
– – ﹤0.01% 587
2023
Q4 		$1K Buy
+35
New +$694 ﹤0.01% 566
2020
Q3 		– Sell
-35
Closed -$1K – 294
2020
Q2 		$1K Hold
35
– – ﹤0.01% 377
2020
Q1 		$1K Hold
35
– – ﹤0.01% 371
2019
Q4 		$3K Buy
+35
New +$4.31K ﹤0.01% 428

Other funds holding SAGE

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

FSA Wealth Management's SAGE Position: Q3 2025 in Review

FSA Wealth Management sold out of Sage Therapeutics (SAGE) in Q3 2025, closing a stake of 35 shares — an estimated $319 sold.

FSA Wealth Management first reported a position in SAGE in Q4 2019 and held it in 9 quarters. The position peaked at $3K in Q4 2019. 5 funds tracked by Wall St. Rank hold SAGE as of Q3 2025.

  • FSA Wealth Management reported no remaining Sage Therapeutics position as of Q3 2025 after selling out during the quarter.
  • FSA Wealth Management sold 35 Sage Therapeutics shares in Q3 2025, an estimated $319.
  • FSA Wealth Management first reported a position in Sage Therapeutics in Q4 2019 and held it in 9 quarters.
  • FSA Wealth Management's Sage Therapeutics position peaked at $3K in Q4 2019.
  • 5 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2025.

Based on FSA Wealth Management's 13F filing for Q3 2025, filed 17 Nov 2025.